Rexahn Adds Drug Conjugate Platform To Its Oncology Offerings

The Rockville, Md.-based biotech hopes to bring more value to shareholders through a slew of polymer-conjugated cancer drugs that it will add to its pipeline while it continues moving its three lead cancer compounds forward.